GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (STU:7CC) » Definitions » Float Percentage Of Total Shares Outstanding

Check-Cap (STU:7CC) Float Percentage Of Total Shares Outstanding : 86.87% (As of Oct. 31, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Check-Cap Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Check-Cap's float shares is 5.08 Mil. Check-Cap's total shares outstanding is 5.85 Mil. Check-Cap's float percentage of total shares outstanding is 86.87%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Check-Cap's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Check-Cap's Institutional Ownership is 0.20%.


Check-Cap Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Check-Cap's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=5.08/5.85
=86.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Check-Cap Business Description

Industry
Traded in Other Exchanges
Address
29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Check-Cap Headlines

No Headlines